5 results about "Plasmin" patented technology

The present invention relates to a polypeptide derived from natural tridegin by structural modification, which may serve as an inhibitor of plasma coagulation factor XIIIa, and to pharmaceutical compositions comprising such polypeptide. The present invention further refers to such polypeptide or pharmaceutical composition for use in a method for treating or preventing a thrombotic event in a patient. Moreover, the invention relates to an endoprosthesis or an enzyme-linked immunosorbent assay (ELISA) plate coated with a polypeptide of the present invention. Furthermore, the invention also encompasses a recombinant fusion protein comprising this polypeptide linked to a fibrinolytic enzyme such as streptokinase, nattokinase or tPAs via a flexible peptide linker containing a thrombin-cleavable site. This construct allows selective inhibition of FXIIIa within a thrombus, while enabling thrombin-triggered release of the fibrinolytic enzyme to induce localized fibrinolysis, thereby achieving targeted dual-action thrombolytic therapy.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

The invention relates a novel isolated recombinant fibrinogen and to a eucaryotic cell producing said novel recombinant fibrinogen, as well as to a fibrin sealant and a fibrin sealant kit comprising the novel isolated recombinant fibrinogen. Furthermore, the present invention relates to a new method for the production of recombinant fibrinogen using eucaryotic cells, and to a new method for identifying novel recombinant fibrinogen variants with reduced sensitivity to proteolytic cleavage by plasmin without losing their suitability as fibrinogen component in a fibrin sealant.

This invention discloses a fibrinolytic enzyme-producing Pseudomonas hygroscopicus originating from mangrove wetlands (… Fictibacillus rigui The strain QMS71 is deposited at the China General Microbiological Culture Collection Center (CGMCC) under accession number CGMCC No. 37018. Under suitable culture conditions, strain QMS71 can produce extracellular enzymes with fibrin-degrading activity. Its fermentation products exhibit significant fibrin degradation activity in vitro and demonstrate thrombolytic and anticoagulant activities in relevant in vitro functional evaluation models. This invention provides a well-identified fibrinolytic enzyme-producing microbial resource and its applications, which can be used for in vitro functional evaluation, model studies, and functional enzymology research related to fibrin degradation.

This invention relates to the field of microbial technology and its application. Xylaria curta (QPZ-01) is deposited at the Guangdong Provincial Microbial Culture Collection Center (GDMCC NO: 64782) on July 10, 2024. The invention also discloses its application in the fermentation of fibrinolytic enzymes. This invention provides an Xylaria curta strain and its application.